Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men

Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.

OBJECTIVES. Our aim was to assess the effect of oral L-arginine on endothelial or platelet physiology in humans. BACKGROUND. L-Arginine is the substrate for nitric oxide synthesis, and in cholesterol-fed rabbits, oral L-arginine improves endothelium-dependent dilation, inhibits platelet aggregation and reduces atheroma. In hypercholesterolemic humans, intravenous L-arginine immediately improves endothelium-dependent dilation; however, the vascular effects of oral L-arginine in healthy humans have not previously been investigated. METHODS. In a prospective, double-blind, randomized crossover trial, 12 healthy young men 27 to 37 years old took L-arginine (7 g three times daily) or placebo for 3 days each, separated by a washout period of 7 to 14 days. RESULTS. After L-arginine, plasma levels of arginine (mean +/- SEM 303 +/- 36 vs. 128 +/- 12 mumol/liter, p = 0.01) and urea (6.7 +/- 0.5 vs. 5.2 +/- 0.2 mmol/liter, p < 0.01) were higher than levels measured after placebo, and platelet aggregation in response to adenosine diphosphate was markedly impaired (37 +/- 12% vs. 81 +/- 3%, p = 0.02). The inhibition of platelet aggregation correlated with the plasma level of L-arginine (r = 0.74, p = 0.01), and it could be completely or partially reversed by ex vivo incubation with N-monomethyl-L-arginine, a specific nitric oxide synthase inhibitor. Platelet cyclic guanosine monophosphate levels were higher after oral L-arginine than at baseline (1.91 +/- 0.46 vs. 1.38 +/- 0.40 pmol/10(9) platelets, p = 0.04). No changes were seen in fasting lipid levels, heart rate, blood pressure, endothelium-dependent dilation of the brachial artery (measured in response to reactive hyperemia, using external vascular ultrasound) (6.1 +/- 0.7% vs. 6.5 +/- 0.7%, p = NS) or in plasma levels of nitrosylated proteins (a marker of in vivo nitric oxide production) (3.5 +/- 0.5 vs. 3.3 +/- 0.4 mumol/liter, p = NS) 1 to 1.5 h after the last dose of L-arginine. CONCLUSIONS. In these healthy young adult men, oral L-arginine inhibited platelet aggregation by way of the nitric oxide pathway. However, it had no effect on systemic hemodynamic variables, plasma nitrosylated protein levels or endothelium-dependent dilation. Therefore, at certain doses, oral L-arginine may result in a relatively platelet-specific increase in nitric oxide production.

This article has been cited by other articles:

				F. Mariotti, J. F. Huneau, I. Szezepanski, K. J. Petzke, Y. Aggoun, D. Tome, and D. Bonnet Meal Amino Acids with Varied Levels of Arginine do Not Affect Postprandial Vascular Endothelial Function in Healthy Young Men J. Nutr., June 1, 2007; 137(6): 1383 - 1389. [Abstract] [Full Text] [PDF]

				G. K. Grimble Adverse Gastrointestinal Effects of Arginine and Related Amino Acids J. Nutr., June 1, 2007; 137(6): 1693S - 1701S. [Abstract] [Full Text] [PDF]

				T. M.C. Brunini, A. C. Mendes-Ribeiro, J. C. Ellory, and G. E. Mann Platelet nitric oxide synthesis in uremia and malnutrition: A role for L-arginine supplementation in vascular protection? Cardiovasc Res, January 15, 2007; 73(2): 359 - 367. [Abstract] [Full Text] [PDF]

				S. G. West, A. Likos-Krick, P. Brown, and F. Mariotti Oral L-Arginine Improves Hemodynamic Responses to Stress and Reduces Plasma Homocysteine in Hypercholesterolemic Men J. Nutr., February 1, 2005; 135(2): 212 - 217. [Abstract] [Full Text] [PDF]

				H. L. Gornik and M. A. Creager Arginine and Endothelial and Vascular Health J. Nutr., October 1, 2004; 134(10): 2880S - 2887S. [Abstract] [Full Text] [PDF]

				S. M Bode-Boger, J. Muke, A. Surdacki, G. Brabant, R. H Boger, and J. C Frolich Oral L-arginine improves endothelial function in healthy individuals older than 70 years Vascular Medicine, May 1, 2003; 8(2): 77 - 81. [Abstract] [PDF]

				B. Venho, S. Voutilainen, V.-P. Valkonen, J. Virtanen, T. A Lakka, T. H Rissanen, M.-L. Ovaskainen, M. Laitinen, and J. T Salonen Arginine intake, blood pressure, and the incidence of acute coronary events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study Am. J. Clinical Nutrition, August 1, 2002; 76(2): 359 - 364. [Abstract] [Full Text] [PDF]

				E. B. Feldman The Scientific Evidence for a Beneficial Health Relationship Between Walnuts and Coronary Heart Disease J. Nutr., May 1, 2002; 132(5): 1062S - 1101. [Abstract] [Full Text] [PDF]

				Z. Kaposzta, P. A. Baskerville, D. Madge, S. Fraser, J. F. Martin, and H. S. Markus L-Arginine and S-Nitrosoglutathione Reduce Embolization in Humans Circulation, May 15, 2001; 103(19): 2371 - 2375. [Abstract] [Full Text] [PDF]

				R. H. Boger, S. M. Bode-Boger, P. S. Tsao, P. S. Lin, J. R. Chan, and J. P. Cooke An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2287 - 2295. [Abstract] [Full Text] [PDF]

				A. Blum, L. Hathaway, R. Mincemoyer, W. H. Schenke, M. Kirby, G. Csako, M. A. Waclawiw, J. A. Panza, and R. O. Cannon III Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women J. Am. Coll. Cardiol., February 1, 2000; 35(2): 271 - 276. [Abstract] [Full Text] [PDF]

				P. M. Kanani, C. A. Sinkey, R. L. Browning, M. Allaman, H. R. Knapp, and W. G. Haynes Role of Oxidant Stress in Endothelial Dysfunction Produced by Experimental Hyperhomocyst(e)inemia in Humans Circulation, September 14, 1999; 100(11): 1161 - 1168. [Abstract] [Full Text] [PDF]

				M. F Bellamy, J. Goodfellow, A. C Tweddel, F. D.J Dunstan, M. J Lewis, and A. H Henderson Syndrome X and endothelial dysfunction Cardiovasc Res, November 1, 1998; 40(2): 410 - 417. [Abstract] [Full Text] [PDF]

				D. Corseaux, T. Le Tourneau, I. Six, M. D. Ezekowitz, E. P. Mc Fadden, T. Meurice, P. Asseman, C. Bauters, and B. Jude Enhanced Monocyte Tissue Factor Response After Experimental Balloon Angioplasty in Hypercholesterolemic Rabbit: Inhibition With Dietary L-Arginine Circulation, October 27, 1998; 98(17): 1776 - 1782. [Abstract] [Full Text] [PDF]

				A. A. Quyyumi Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia?: A double-blind comparison of parenteral D- and L-Arginine J. Am. Coll. Cardiol., October 1, 1998; 32(4): 904 - 911. [Abstract] [Full Text] [PDF]

				J. G. Diodati, N. Dakak, D. M. Gilligan, and A. A. Quyyumi Effect of Atherosclerosis on Endothelium-Dependent Inhibition of Platelet Activation in Humans Circulation, July 7, 1998; 98(1): 17 - 24. [Abstract] [Full Text] [PDF]

				N. Dakak, S. Husain, D. Mulcahy, N. P. Andrews, J. A. Panza, M. Waclawiw, W. Schenke, and A. A. Quyyumi Contribution of Nitric Oxide to Reactive Hyperemia : Impact of Endothelial Dysfunction Hypertension, July 1, 1998; 32(1): 9 - 15. [Abstract] [Full Text] [PDF]

				G. Theilmeier, J. R. Chan, C. Zalpour, B. Anderson, B.-y. Wang, A. Wolf, P. S. Tsao, and J. P. Cooke Adhesiveness of Mononuclear Cells in Hypercholesterolemic Humans Is Normalized by Dietary L-Arginine Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3557 - 3564. [Abstract] [Full Text]

				C. Greenlees, R. M Wadsworth, P. A Martorana, and C. L Wainwright The effects of L-arginine on neointimal formation and vascular function following balloon injury in heritable hyperlipidaemic rabbits Cardiovasc Res, August 1, 1997; 35(2): 351 - 359. [Abstract] [Full Text] [PDF]

				Y. Mitani, K. Maruyama, and M. Sakurai Prolonged Administration of L-Arginine Ameliorates Chronic Pulmonary Hypertension and Pulmonary Vascular Remodeling in Rats Circulation, July 15, 1997; 96(2): 689 - 697. [Abstract] [Full Text]

				M. R. Adams, W. Jessup, D. Hailstones, and D. S. Celermajer L-Arginine Reduces Human Monocyte Adhesion to Vascular Endothelium and Endothelial Expression of Cell Adhesion Molecules Circulation, February 4, 1997; 95(3): 662 - 668. [Abstract] [Full Text]

				T. S. Rector, A. J. Bank, K. A. Mullen, L. K. Tschumperlin, R. Sih, K. Pillai, and S. H. Kubo Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients With Heart Failure Circulation, June 15, 1996; 93(12): 2135 - 2141. [Abstract] [Full Text]